Skip to content
Peptide research

Ipamorelin

Also known as Ipamoreline · NNC 26-0161 · IPAM
Category
Growth Hormone
Administration routes
Injectable
Regulatory status
Not FDA-approved

What it is

A synthetic five-amino-acid peptide that selectively prompts pulse-like growth hormone release, marketed for anti-aging, muscle, and recovery. Selective GH release and short-term safety have moderate support, but fat-loss and bone claims rest mostly on animal data or theory, so the human case is weak. Only three published human studies exist and it stalled at Phase II. Not an approved US drug; sold mostly as research-grade material of uncertain purity.

Read Full record

Studied uses & evidence

Studied uses(7)

  • Selective GH release

    Medium

    Raises GH, with ACTH and cortisol responses similar to GHRH in animal studies.

  • Body composition

    Speculative

    Lean-mass and fat-loss effects are inferred from animal growth data and the GH/IGF-1 mechanism.

  • Bone growth/density

    Low

    Dose-dependent bone growth in rats, reflecting larger bone size rather than higher density.

Evidence limits

Evidence Level
Limited Clinical

PK study in healthy males (1999), Phase II POC for postop ileus (n=114, 2014), Phase II dose-finding bowel resection (n=320). POC well-tolerated but missed primary endpoint (p=0.15). Developed by Novo Nordisk, later licensed to Helsinn, did not advance past Phase II.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

Do not use if

  • Pituitary tumors

    Absolute

    Directly stimulates the pituitary. Contraindicated with pituitary adenomas.

  • Active cancer

    High

    Growth hormone elevation may promote tumor growth through IGF-1 pathway.

  • Diabetic retinopathy

    High

    GH/IGF-1 elevation can worsen diabetic retinopathy.

General cautions

  • Pregnancy

    Absolute

    No reproductive safety data.

Risk summary(5)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Limited human clinical data (3 published studies)

    Moderate
  • Long-term safety data lacking

    Moderate
  • Did not advance past Phase II clinical trials

    High
  • Potential GH-related effects: water retention, joint discomfort

    Moderate
  • Theoretical concerns with prolonged GH/IGF-1 elevation and cancer risk

    Theoretical
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.